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Abstract 
This paper assesses the magnitude of Pb uptake in cortical and trabecular bones in 
healthy animals and animals with altered balance in bone turnover, and the impact of 
exposure to Pb on serum markers of bone formation and resorption. The results reported 
herein provide physiological evidence that Pb distributes differently in central 
compartments in Pb metabolism, such as cortical and trabecular bone, in healthy 
animals and animals with altered balance in bone turnover, and that exposure to Pb does 
have an impact on bone resorption resulting in OC-dependent osteopenia. These 
findings show that Pb may play a role in the etiology of osteoporosis and that its 
concentration in bones varies as a result of altered bone turnover characteristic of this 
disease, a long standing question in the field. In addition, data collected in this study are 
consistent with previous observations of increased half-life of Pb in bone at higher 
exposures. This evidence is relevant for the necessary revision of current 
physiologically based kinetic models for Pb in humans. 
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1. Introduction  
 
Studies have confirmed that levels of lead (Pb) exposure lower than the present 
acceptable cutoff points are associated with increased mortality [1]. Physiologically 
based kinetic models (PBKM) representing the skeletal uptake, retention, and clearance 
of Pb in humans have long been in use and are important to define guidelines for 
prevention in occupational and environmental exposure to Pb. These models were 
developed before large epidemiological data sets including bone Pb were available and 
are limited to the data they are based on, which only in a few cases were collected in 
humans [2]. In particular, two widely used models, namely the Leggett and O’Flaherty 
models [3,4], were shown not to fit well epidemiological data from surveys of 
occupationally exposed populations, and require significant adjustments in their default 
transfer rates before some consistency between the observed and predicted bone Pb 
concentrations can be achieved [5,6].  
 
In effect, it has been shown that a reduction by a factor of 5 in the default transfer rate 
from cortical bone to plasma in the O’Flaherty model was required to achieve some 
consistency between model predictions and data representative of occupational 
exposures [5]. The same authors report also that consistency between the model 
predictions and the data for trabecular bone was not achieved even after the 
corresponding default transfer rate from bone to plasma was reduced by a factor of 4. 
Moreover, data from a repeat bone Pb survey performed with occupationally exposed 
subjects showed that people aged less than 40 years have shorter half-life for Pb in tibia 
than did those older than 40, and that less intensely exposed subjects have shorter tibia 
Pb half-life than those with higher exposure [7,8]. In an independent approach to the 
transfer of Pb between body compartments, the earlier observation of the age- and 
exposure dependence of the transfer rate of Pb from bone to blood was confirmed and 
refined [9]. In addition, when the transfer rates thus derived were used to replace the 
default values in the Leggett model, a better agreement between measured and predicted 
bone Pb could be observed [6].  
 
These results contrast with the assumption in the Leggett and O’Flaherty models that 
the transfer rate of Pb from bone to blood is both constant in adulthood and independent 
of bone Pb concentration. Moreover, current PBKM describe the distribution of Pb in 
the body under the assumption of balance between bone formation and bone resorption, 
which is not compatible with known age-related bone loss patterns for men (0.5 to 1% 
/year) and women (1% to 6% /year) starting around the age of 40 years [10]. Therefore, 
it is important to know how unbalanced bone formation and resorption affect the 
distribution of Pb in the body and the models’ output, as well as to establish the relative 
importance of Pb exposure on the rates of bone formation and resorption. Altogether, 
these results imply that current PBKM for Pb in humans should be revised to account 
for kinetic rates varying with age and exposure level.  
 
Pb exposure is also associated with reduced bone mass and quality which may 
predispose to osteoporosis [11], a disease which clinical and public health importance is 
due to the associated fractures. The diagnosis of osteoporosis is centered on the 
assessment of bone mineral density (BMD), typically by single or dual X-ray 
absorptiometry (DXA) [12]. DXA alone is not optimal to detect people at high risk of 
fracture because it is bone strength that determines the fracture risk [10,13]. Other 
factors, such as age, sex, degree of bone turnover, glucocorticoid use, secondary 
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osteoporosis, either independently or in correlation with BMD, have been proven to 
contribute to fracture risk [10,14]. Information on validated risk factors other than BMD 
is necessary and, among those, indices of bone turnover, have been identified as factors 
that can enhance the predictive value of BMD [10,15]. 
 
The few human studies of Pb in the etiology of osteoporosis are focused on the 
association between Pb exposure and Bone Mineral Density (BMD) and have drawn 
divergent conclusions. Only one study relates changes in blood and bone Pb with 
increased bone resorption [16]. When current blood or urinary Pb are used as biological 
markers, Pb exposure and BMD have either no association [17,18], or an inverse 
association, in Hispanic white males only [19], and in former female Pb smelters [20]. 
When cumulative blood Pb or bone Pb assessed by in vivo 
109
Cd KXRF are used as 
biological markers, Pb exposure and BMD have a direct association [21], suggesting 
that Pb may well have a beneficial health effect. This was later considered a spurious 
association, due to the fact that the presence of Pb interferes with the accurate 
measurement of BMD by DXA, because of its higher attenuation coefficient compared 
to calcium [22]. Despite the significant contribution on in vivo bone Pb surveys to a 
better understanding of Pb metabolism is humans, the relationships between the 
concentration of Pb in bone and the rate of Pb removal from bone cannot be fully 
addressed by such surveys. The epidemiological data thus collected would convey 
information on the co-variation between the bone Pb concentrations and the rate of Pb 
removal from bone but would not help to clarify whether Pb is a causative agent of 
increased bone turnover or if its concentration in blood and bones varies as a result of 
increased bone turnover [23].  
 
Cleary the best means for investigating the relationships between Pb distribution in the 
body and altered bone turnover is to use an animal model. Although it is debatable 
whether the coupled processes of bone formation and resorption that occur in rodents 
represent true bone remodeling, several reliable murine and rat models for both 
increased and decreased bone mass have been developed, which use is required by 
regulatory agencies such as the U.S. Food and Drug Administration for testing all 
antiosteoporosis therapeutics [24].  
 
This paper assesses the magnitude of Pb uptake in cortical and trabecular bones in 
healthy animals and animals with altered balance in bone turnover, and the impact of 
exposure to Pb on serum markers of bone formation and resorption. Such relationships 
are useful for the research community interested in modeling the metabolic pathways of 
Pb in humans, because they provide physiological evidence for the necessary refinement 
of kinetic parameters governing the Pb transfer between blood and the compact and 
cortical bone tissues. In sum, the results presented herein will help to clarify whether Pb 
may play a role in the etiology of osteoporosis or if its concentration in blood and bones 
varies as a result of increased bone turnover characteristic of this disease.  
 
2. Materials and methods 
 
2.1 Animal experiments 
 
The animal experiments in this study were approved by the Ethics Committee of the 
Instituto Superior de Ciências da Saúde Egas Moniz and performed in accordance with 
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the Portuguese Law and EU Directive 2010/63/EU on animal research. All animals 
were held in a licensed animal facility. 
 
2.1.1 Experiment I 
 
In order to assess Pb uptake in cortical and trabecular bone in the case of unbalanced 
bone formation and resorption, 47 female Wistar rats with 11 weeks of age were 
randomly assigned to three groups and kept in tall cages with 2 – 3 animals per cage. 
The following groups were considered: Normal group (n = 16) of intact rats; OVX 
group (n = 18) composed by animals who were ovarietomized between the 11
th
 and 12
th
 
week of age; and EST group (n = 13) with animals who were to receive estrogen 
supplement treatment (EST) by means of subcutaneous administration of unopposed 
17-estradiol, at 6 and 9 months of age. Prior to ovariectomy, all rats were anesthetized 
by an intraperitoneal injection of xylazine (10 mg/kg Rompun 2% Bayer) and ketamine 
(50 mg/kg Imalgene 1000, Merial), and OVX was performed from a dorsal approach 
[25]. Success of OVX was confirmed later at sacrifice, by failure to detect ovarian tissue 
and observation of marked atrophy of the uterine horn. In the EST group, animals were 
given subcutaneous implants of 17-estradiol pellets (90-day release, 0.025 mg/pellet 
IRA), via a small incision in the skin of the neck just behind the right ear under brief 
isofluorane anesthesia. In view of published data, this slow-release dosing regimen is 
deemed to result in a 10 to 30% increase of physiological plasma estradiol levels in 
intact female and male Wistar rats [26,27,28]. All animals were fed the same diet, 
adequately for daily requirements but not ad lib in order to avoid obesity. Obesity was 
monitored through regular assessment and recording of body weight. The diet was 
analyzed to ensure that it was Pb free.  
 
From age 6-month on, animals in each of the 3 groups received the same dose of Pb 
acetate in water (500 ppm) for 6 months. At the end of this exposure to Pb, all animals 
included in the experiment were sacrificed using Euthanasia of Rodents by Carbon 
Dioxide, for the measurement of all the dependent variables. The excised bones were 
the lumbar vertebrae and femora. Selection of these particular bones results from the 
fact that the vertebrae, predominantly trabecular bone tissue, reflect mostly intermediate 
exposure to Pb, while the femora, predominantly cortical bone, reflect long-term 
exposure, and thus, represent two body compartments with different Pb kinetics. 
Moreover, these bones represent the bone sites where the incidence of osteoporotic 
fractures is highest in humans. In addition, approximately 1 mL of blood was collected 
by cardiac puncture for the assessment of markers of bone formation and resorption. 
 
At the end of this experiment, complete records for bone Pb concentrations and serum 
concentrations of markers of bone formation and resorption were available for 43 
animals, with the following distribution: 16, 10 and 17, in the Normal, EST and OVX 
groups, respectively. A priori power analysis with a one-way ANOVA model for an 
expected large effect size induced by the experimental protocol, estimated a total 
sample size of at least 25 subjects for a minimum power of 80% at the 5% level of 
significance, which by far insures that the detected effects were not due to chance.  
 
2.1.2 Experiment II 
 
To assess the impact of exposure to Pb on the biochemical markers of bone turnover, 
four groups of adult (6 months) female Wistar rats were formed, in a total of 62 
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subjects. Group assignment, cage distribution and feeding were as described in 
experiment I. One group was taken as control (Group 1, n = 16) while the remaining 
three groups received 50 (Group 2, n = 15), 200 (Group 3, n = 16) and 500 (Group 4, n 
= 15) ppm of Pb acetate in drinking water, for a period of 6 months.  
 
At baseline, 5 animals from each group were sacrificed, using Euthanasia of Rodents by 
Carbon Dioxide, for excision of lumbar vertebrae and femora bones. Two animals in 
Group 1 and another 2 in Group 2 have died after the onset of exposure. After the 6-
month exposure, the remaining animals were euthanized for bone excision and blood 
collection, following the methods already described.  
 
At the end of exposure to this specific experiment, complete records for bone Pb 
concentrations and serum concentrations of markers of bone formation and resorption 
were available for 31 animals, with the following distribution: 8, 6, 8 and 9, in Group 1, 
2, 3 and 4, respectively. A priori power analysis with a one-way ANCOVA model for 
an expected large effect size induced by the intended treatment, estimated a total sample 
size of at least 31 subjects for a minimum power of 80% at the 5% level of significance. 
Therefore, the sample size at the end of the experiment was large enough to insure that 
the detected effects were not due to chance.  
 
In both experiments, all collected bone and blood derived samples were fresh frozen 
until measurements were performed. 
2.2 Assays of biomarkers of bone turnover 
 
Most biochemical indices of bone resorption are related to collagen breakdown products 
or the various collagen cross-links and telopeptides. In contrast, markers of bone 
formation are either by-products of collagen neosynthesis or osteoblast-related proteins, 
such as osteocalcin [29]. In rats, circulating osteocalcin (OC) originates from new bone 
synthesis rather than the breakdown of bone and serum levels of immunoreactive OC 
have been shown to correlate well with the bone formation rate as assessed by 
histomorphometry [29,30]. In contrast, bone resorption rate cannot be measured directly 
by histomorphometry but can be measured indirectly as changes in bone formation rate 
by the measured rate of change in bone volume, although it is one of the derived indices 
which use is somewhat clouded with issues of reasonability and rigor of the underlying 
assumptions [31]. At present, serum C-terminal peptide-bound crosslinks of Type I 
collagen (CTX-1) has been chosen as the reference standard for bone resorption rate, 
following a well described rationale in the literature [32].  
 
In this context, OC and CTX-1 markers of bone turnover were assessed in the serum of 
fasting rats of the different groups considered in both experiments in this study. In order 
to control for circadian variations of circulating OC and CTX-1, blood collection has 
been performed in the same period of the day (9 to 11 am). Approximately 1 mL of 
blood was collected by cardiac puncture and two ELISA kits were used to for the 
quantification of osteocalcin (Rat-MIDTM osteocalcin from IDS) and CTX-1 (RatLaps 
TM ELISA (CTX-1), from IDS) in rat serum. After the usual procedures described in 
the protocols provided by the ELISA Kit suppliers, RatLaps antigens in each sample 
were measured in an ELISA Microplate Reader at 450 nm. 
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2.3 Bone Pb determinations 
 
The concentration of Pb in compact and trabecular animal bones was determined by 
wavelength dispersive X-ray fluorescence (WDRXF) spectrometry, using  a commercial 
4 kW X-ray fluorescence spectrometer (S4 Pioneer, Bruker AXS) equipped with a Rh 
X-ray tube with a 75 mm Be end window and a 34 mm diameter collimator mask.  
 
The feasibility of the WDXRF method for the assessment of Pb in animal bone powder 
was demonstrated and described in detail elsewhere [33]. In brief, excised femora and 
lumbar vertebrae were prepared in the following sequence: 24 hour ultrasound bath in 
distilled water, that helped remove the remaining soft tissues at the bone surface using a 
surgical scalpel with a stainless steel blade; 24 hour freeze drying, with a multipurpose 
ice condenser (ModulyoD-230, Thermo Savant) operated at a nominal temperature of -
50 ºC, to remove any excess water; and grinding in an agate mortar to reduce the 
samples to a fine powder. Median particle length was 180 µm, as determined by light 
microscopy after sieving the bone powder through a 355 µm opening grid and its 
dispersion in water. High-density polyethylene X-ray fluorescence sample cups with 
35.8 mm diameter assembled with a 4 µm prolene film were used to support the bone 
powder sample. The polyethylene cup was placed in steel sample cup holders with an 
opening diameter of 34 mm. Bone mass was in the range of 1 to 2.2 g for vertebrae and 
1 to 1.5 g for femora, which produced samples of bone powder with heights between 1 
and 2 mm.  
For the calibration of the WDXRF system, a set of 9 synthetic standards were prepared 
in triplicate by doping calcium carbonate (CaCO3) with known amounts of Pb(II) 
acetate (C4H6O4Pb3·H2O). Measurements were performed in helium mode, with fixed 
measurement times (180 s) which insured a counting statistical error of not more than 
5% for a 3 criterion. The estimated detection limit was 1.7 ppm, while intra-assay 
precision, assessed at 3 concentration levels (10, 150 and 250 ppm) as the coefficient of 
variation of 12 repeat measurements, was in the range 0.3% to 7.6%.  The accuracy of 
the method was established through the measurement of the NYS Reference Materials 
05-02 through 04 showing good agreement with certified values [34]. 
3. Results  
 
3.1 Experiment I 
 
The body weight (in g) of the 43 animals with complete records at the end of the 
experiment is presented in table 1, at baseline and endpoint. No differences concerning 
the body weight were observed between groups both at the baseline (p = 0.219) and 
endpoint (p = 0.131), as shown by the non-parametric Kruskal-Wallis test. 
 
Table 1 
Mean ± Standard Deviation of body weight (in g) of normal, estrogen supplement treated (EST) and 
ovariectomized (OVX) animals, at baseline and after exposure (experiment I). 
Time Normal EST OVX 
Baseline 348.7 ± 17.9 358.0 ± 33.6 372.7 ± 32.3 
Endpoint 420.3 ± 66.5 440.4 ± 42.4 457.5 ± 38.3 
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Table 2 
Mean ± Standard Deviation and range of serum levels of OC and CTX and Pb concentrations in cortical 
and trabecular bone in normal, estrogen supplement treated (EST) and ovariectomized (OVX) animals, 
after exposure (experiment I). 
Biological marker Normal EST OVX 
OC (ng/mL) 
165.0 ± 55.8 
(88.6 – 290.7) 
141.2 ± 37.9 
(74.0 – 193.2) 
103.5 ± 53.6 
(40.6 – 234.6) 
CTX (ng/mL) 
8.8 ± 1.9 
(5.8 – 12.2) 
8.2 ± 1.7 
(5.4 – 11.8) 
7.9 ± 4.4 
(4.1 – 21.9) 
Cortical bone Pb (ppm) 
79.1 ± 18.0 
(46.0 – 112.0) 
104.7 ±21.1 
(66.0 – 134.0) 
59.2 ± 25.2 
(32.0 – 142.0) 
Trabecular bone Pb (ppm) 
104.6 ± 25.3 
(65.0 – 152.0) 
154.2 ± 35.1 
(114.0 – 207) 
80.4 ± 32.2 
(44.0 – 187.0) 
 
 
Table 2 shows the concentration of Pb in cortical and trabecular bone in the 3 groups 
considered in this experiment and their serum levels of the markers of bone formation 
and resorption, the main processes governing bone remodeling, and therefore the intake 
and release of Pb by bone.  
 
As is well known, the process of bone remodeling is the coupling of osteoclastic bone 
resorption followed by osteoblastic bone formation, under tight regulation by systemic 
hormones and by local factors released by osteoclasts and osteoblasts with reciprocal 
regulatory effects on their activity [35]. In humans, bone remodeling takes place in bone 
metabolic units (BMU); however, rodents lack traditional BMUs, so it is debatable 
whether the coupled processes of formation and resorption that occur in rats represent 
true remodeling [24]. In this work, such coupling processes were far from being ruled 
out by the observed significant inverse correlation between the serum concentrations of 
OC and CTX, as expressed by a Spearman correlation coefficient of -0.461 (p = 0.009).   
 
Therefore, in the analysis of each the bone turnover markers across groups, it is 
necessary to remove from that comparison the association with the other marker. This 
was implemented using a One-Way ANCOVA model including the serum level of each 
marker of bone turnover as dependent variable, the group as independent factor and the 
serum level of the other marker as covariate.  
 
Regardless of the marker used as dependent variable in the ANCOVA model, a 
significant interaction was detected between the covariate and the independent factor. 
Therefore, post-hoc group comparisons were performed through planned contrasts, at 
the 25
th
, 50
th
 and 75
th
 percentiles of the serum concentrations for each marker of bone 
turnover. These percentiles were 91.2, 129.6 and 169.0 ng/mL, for OC and 6.0, 8.0 and 
9.0 ng/mL for CTX. The results of these planned contrasts are shown in table 3. In 
general, differences between the groups were more evident for serum OC than for serum 
CTX, with OVX animals showing significantly lower serum OC levels than normal and 
EST animals, nearly over the considered range of serum CTX. Concomitantly, OVX 
animals also showed a trend for higher serum CTX than normal and EST animals with 
increasing serum OC, although significant differences were only achieved or suggested  
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Table 3 
Estimated contrasts (ij)
a
 in serum CTX (and OC) in different exposure groups, over the range of serum 
OC (CTX) values. Values between brackets refer to the contrast significance (experiment I).  
DV
b
: CTX Serum OC 
percentile 
EST Group OVX Group 
 
Normal Group 
25 NE = 0.443 (0.832) NO = 2.183 (0.104) 
50 NE = 0.788 (0.514) NO = -0.137 (0.900) 
75 NE = 1.113 (0.337) NO = -2.456 (0.056) 
 
 
EST Group 
25  EO = 1.740 (0.286) 
50 EO = -0.125 (0.428) 
75 EO = -3.600 (0.022) 
 
DV: OC Serum CTX 
percentile 
EST Group OVX Group 
 
Normal Group 
25 NE = 30.157 (0.361) NO = 99.581 (<0.001) 
50 NE = 29.435 (0.150) NO = 67.943 (<0.001) 
75 NE = 29.075 (0.169) NO = 51.974 (0.004) 
 
 
EST Group 
25  EO = 69.424 (0.015) 
50 EO = 38.408 (0.051) 
75 EO = 22.999 (0.276) 
a NE  - mean contrast between Normal and EST groups; NO  - mean contrast between Normal and OVX groups;   
EO  - mean contrast between EST and OVX groups 
b DV – Dependent variable in the ANCOVA model 
 
at higher serum OC in these groups. Moreover, normal and EST animals did not show 
any differences in what concerns serum OC and CTX.  
 
Finally, one-way ANOVA has been used to compare the Pb concentration of the 
different groups, in both cortical and trabecular bone, after validation of the assumption 
of homogeneous variances across groups with the Levene test (p > 0.05, for both 
bones). Following ANOVA, significant differences were detected between groups for 
the Pb concentration in cortical bone (p < 0.001), with an observed power of 99.9%. 
Post-hoc comparisons using the Tukey’s test have detected significantly higher Pb 
concentrations in cortical bone in the EST group than in the normal (p < 0.001) and the 
OVX (p < 0.001) groups. Moreover, Pb concentrations in cortical bone of OVX animals 
were significantly lower than those of normal animals (p = 0.030).  
 
Similar results were observed for trabecular bone. In fact, significant differences were 
detected between groups for the Pb concentration in trabecular bone (p < 0.001), with 
an observed power in excess of 99.9%, according to ANOVA. Again, significantly 
higher Pb concentrations were observed in the trabecular bone of the EST group, in 
comparison to the normal (p < 0.001) and the OVX (p < 0.001) groups. Finally, lower 
Pb concentrations in the trabecular bone of OVX animals, in comparison to normal, 
were also suggested by the post-hoc Tukey’s test, although the difference did not reach 
statistical significance (p = 0.068). 
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Table 4  
Mean ± Standard Deviation of body weight (in g), at baseline and after exposure (experiment II). 
Time Group 1 Group 2 Group 3 Group 4 
Baseline 336.3 ± 7.5 319.3 ± 11.0 326.5 ± 2.1 329.3 ± 21.3 
Endpoint 389.7 ± 13.0 409.0 ± 28.6 385.5 ± 10.6 380.3 ± 28.0 
 
 
Table 5 
Mean ± Standard Deviation and range of serum levels of OC and CTX and bone Pb concentrations in 
cortical and trabecular bone in the 4 groups of animals, after exposure (experiment II). 
Biological marker Group 1 Group 2 Group 3 Group 4 
OC (ng/mL) 
88.2 ± 34.5 
(54 – 161.0) 
107.4 ± 32.7 
(60.0 – 137) 
106.0 ± 33.5 
(36.1 – 131.0) 
99.4 ± 39.4 
(47.8 – 171.5) 
CTX (ng/mL) 
14.1 ± 3.1 
(9.5 – 18.1) 
17.4 ± 4.0 
(12 – 20.5) 
17.6 ± 4.9 
(12.3 – 26.3) 
21.2 ± 5.0 
(13.8  – 30.8) 
Cortical bone Pb (ppm) < DL
b
 
2.5 ± 0.9 
(2.0 – 3.0) 
21.4 ±7.2 
(13.0 – 31.0) 
80.4 ± 26.0 
(44.0 – 126.0) 
Trabecular bone Pb (ppm) < DL 
4.0 ± 1.0 
(3.0 – 5.0) 
34.1 ± 11.9 
(21.0 – 51.0) 
128.1 ± 39.8 
(67.0 – 190.0) 
b DL – Detection limit of the WDXRF technique used for bone Pb determinations (1.7 ppm) 
 
 
3.2 Experiment II 
 
Table 4 presents the body weight (in g) of the 31 animals with complete records for 
bone Pb and OC and CTX concentrations in the different groups, at baseline and end of 
the 6-month exposure to Pb in water. No differences in the body weight were detected 
between groups, both at baseline (p = 0.461) and end of exposure (p = 0.091), according 
to the Kruskal-Wallis test. For the same animals, the serum levels of OC and CTX and 
the concentration of Pb in cortical and trabecular bone are presented in Table 5. 
 
In view of the abovementioned coupling of bone formation and resorption, when 
comparing the different exposure groups for their serum levels of either CTX or OC, it 
is necessary to remove from each comparison the association between serum levels of 
CTX and OC. This was implemented using a One-Way ANCOVA model including the 
serum level of each marker as dependent variable, the exposure group as independent 
factor and the serum level of the other marker as covariate.  
 
In these conditions, for the model including serum CTX as dependent variable, one-way 
ANCOVA has detected a significant interaction between the covariate OC and exposure 
group (p = 0.015), with an observed power of 80.0%. In addition, significant differences 
(p = 0.010) in the serum levels of CTX were detected between exposure groups, with an 
observed power of 84.3%. Finally, no significant differences in the serum levels of OC 
were observed between exposure groups, although such effect was suggested by the 
data (p = 0.064).  
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Table 6 
Estimated contrasts (ij)
a
 in serum CTX in different exposure groups, over the range of serum 
OC values. Values between brackets refer to the contrast significance (experiment II).  
 Serum OC 
percentile 
Group 2 Group 3 Group 4 
Group 1 25 12 = -9.7 (0.001) 13 = -5.2 (0.068) 14 = -7.9 (0.002) 
50 12 = -4.9 (0.043) 13 = -4.5 (0.049) 14 = -7.6 (0.002) 
75 12 = -0.7 (0.830) 13 = -3.9 (0.200) 14 = -7.3 (0.015) 
 
Group 2 25  
 
23 = 4.5 (0.151) 24 = 1.8 (0.496) 
50 23 = 0.5 (0.843) 24 = -2.6 (0.246) 
75 23 = -3.2 (0.258) 24 = -6.6 (0.017) 
 
Group 3 25   34 = -2.7 (0.340) 
50 34 = -3.1 (0.148) 
75 34 = -3.4 (0.139) 
a ij - mean contrast group i and group j 
 
The abovementioned significant interaction, the dominant effect in the ANCOVA 
model, shows that the effects of exposure to Pb on the serum level of CTX depend on 
the serum level of OC. Consequently, post-hoc group comparisons were performed at 
reference levels of serum OC, through planned contrasts as described in the literature 
[36]. The reference levels were set at 74, 104 and 131 (ng/mL), respectively the 25
th
, 
50
th
 and 75
th
 percentiles of serum OC. Table 6 presents the results of these planned 
contrasts, where ij is the estimated contrast, defined as the difference between the 
means of serum CTX in group i and group j. 
 
These results show that serum CTX was significantly higher in the exposed groups than 
in the non-exposed group, over the considered range of serum OC. Moreover, the 
exposed groups did not differ amongst themselves in serum CTX over nearly the whole 
range of serum OC, except for groups 2 and 4 at the upper quartile of serum OC, in 
which case higher serum CTX was observed in the highest exposed group.   
 
4. Discussion 
 
It is generally accepted that OVX in rats increases bone resorption and bone formation, 
leading to bone loss [24,37], whereas EST by means if administration of unopposed 
17-estradiol induces rapid suppression of bone resorption markers and a delayed 
decrease in bone formation markers [29]. While the supporting evidence for the 
expected response to OVX has been provided by the technique of bone 
histomorphometry [37], the expected changes induced by EST are supported by studies 
which have assessed urine and serum markers of bone turnover [29].  
 
In this study (experiment I), a 6-month exposure to the same dose of Pb in water 
resulted in significantly higher serum CTX and lower serum OC levels in the OVX 
group, in comparison with normal and EST female Wistar rats. In addition, markers of 
bone formation and resorption were both lower in EST than in normal animals, although 
the differences did not reach statistical significance. These results agree with the 
generally accepted view for the post-OVX induced changes on bone resorption markers, 
but are at variance with the expected changes on bone formation markers, and for the 
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EST induced changes in bone turnover markers, despite the lack of statistical 
significance.  
 
To begin with, it is noted that increased bone resorption and decreased bone formation, 
as observed in the OVX group in this study, may result in osteopenia and this is the 
expected outcome in a model for decreased bone mass such as OVX [24]. Also, the fact 
that increased serum CTX in the OVX group was strongly suggested in comparison 
with the normal animals, and was statistically significant in comparison to the EST 
group, in both cases only at the upper quartile of the range of serum OC, cannot be ruled 
out in view of published data. In fact, it has been reported that OC levels can influence 
changes of bone parameters which impact on bone strength or bone turnover, as a result 
of changes in bone metabolism. For example, it was shown that OVX-induced 
decreases in bone maturity could only be detected at high bone OC levels, whereas 
OVX-induced decreases in bone mass parameters could only be detected at low bone 
OC levels [38]. Moreover, one must use caution when contrasting the observed data 
with the accepted view, due to the number of factors that determine the outcome of in 
vivo studies, namely age of animal at the time of OVX and the time post-OVX when the 
measurements are made [37], and due to the fact that the studies supporting such view, 
put aside some methodological issues, only considered cases of OVX and EST 
uncomplicated by Pb exposure. The current view for the response of rats to OVX-
induced osteopenia relies largely on a few studies using histomorphometry analysis of 
static and dynamic parameters of bone turnover [37]. Since static parameters are not 
indicative of cellular activity and corresponding bone formation and resorption rates, the 
contrast with the accepted view will focus on the dynamic parameters which are more 
meaningful as indices of bone formation rate [39].  
 
In brief, it has first been reported that, at 5 weeks post-OVX performed on rats of 
approximately 75 days of age, all histomorphometric indices of bone formation rate in 
OVX animals were increased in comparison with normal rats [40]. Later, the same 
group has reported that, at different times from 14 to 180 days post-OVX performed on 
90-day old rats, some, but not all, indices of bone formation rate already considered in 
the previous work differed between OVX and normal rats [39]. However, these 
conclusions are clouded with issues of correctness affecting the analysis of the data. 
First, the high standard deviations in the dynamic parameters of bone formation, as 
noted by the authors themselves [40], jeopardize the conclusion of post-OVX increases 
in bone formation rates. Second, it is not immediately clear how a truly two-factorial 
design and a clear interaction between time and animal status, which is obvious from 
the depicted data, was tackled by using a two-tailed Student´s t-test for group 
comparisons at different time points [39]. Actually, recent research using more 
appropriate statistical analysis of the data has concluded that none of the 
histomorphometric indices of bone formation rate was different between OVX and 
normal rats, at any time point from 6 weeks to 9 months post-OVX performed at 10 
months of age [41]. However, these studies only considered the case of OVX and EST 
uncomplicated by Pb exposure. Because Pb competes with calcium and replaces it in 
bones [3,4], it is conceivable that it could interfere with the expected response to OVX 
by decreasing mineral apposition rate, and therefore, bone formation rate. This is 
consistent with the observation that, at 9 months post-OVX, OVX animals had already 
lower, although non-significant, mineral apposition rates than controls [37].  
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Moreover, in what concerns the lack of statistical significance of the EST induced 
decrease in bone turnover markers observed in this work in comparison with normal 
rats, it is first noted that 17-estradiol has been administered as an antiresorptive agent 
usually in ovariectomized rats [29], not on intact animals exposed to Pb, and at much 
higher dosing regimens than that used in this study [26,27,28]. Conceivably, Pb 
exposure combined with a low-dose, slow-release EST regimen administered to normal 
rats, may moderate the expected decrease in bone turnover markers induced by EST 
administered in the abovementioned standard conditions, and thus, result in a non 
significant change.  
 
Therefore, despite some divergence with the generally accepted view for the post-OVX 
and the EST induced changes in bone turnover markers, the observed results in this 
work are consistent with published data and, more importantly, with the observed 
pattern of Pb accumulation in bone of the normal, OVX and EST animals considered in 
this study, which is addressed next.   
 
In fact, one main finding of this study (experiment I) was that a 6-month exposure to the 
same dose of Pb in water resulted in significantly different Pb uptake by both cortical 
and trabecular bone between normal, EST and OVX female Wistar rats. In current 
PBKM it is assumed that Pb is incorporated from plasma into forming bone at a rate 
proportional to the bone formation rate, and is removed from bone to plasma as bone is 
resorbed at a rate proportional to the bone resorption rate [3,4]. In view of this 
assumption, the observed differences in Pb uptake by bone should relate to differences 
in the serum OC and CTX levels observed between those groups of animals at the end 
of exposure. As a matter of fact, increased Pb removal and decreased Pb incorporation 
by bone, and consequently decreased bone Pb accumulation, are expected from the 
increased bone resorption and decreased bone formation observed in the OVX group, in 
comparison with the normal and EST groups. In addition, if just the direction of the 
contrasts is considered, the increased bone Pb concentrations in the EST group in 
comparison with normal animals may conceivably follow from the decreased bone 
resorption and bone formation in the former group, according to the generally accepted 
view for the EST induced changes on markers of bone turnover. However, how the 
significant marked differences in bone Pb concentrations follow from non-significant 
contrasts in bone turnover markers at the end of the 6-month exposure is unclear. 
Possibly, the initial rapid and marked suppression of bone resorption and delayed 
decrease in bone formation induced by the administration 17-estradiol favored an 
initial rapid and marked increase in bone Pb concentrations in the EST group, in 
comparison of that of normal animals, a contrast which remained until de end of 
exposure. Concomitantly, the higher bone Pb concentrations in the EST group would 
have induced an increase of bone resorption as suggested by the results in experiment II 
of this study, to a greater extent than in the normal group, and thus, leveling bone 
resorption in both groups at the end of exposure.   
 
In sum, these results show that Pb distributes in a significantly different manner in both 
compact and trabecular bone, two central compartments in Pb metabolism, in the case 
of unbalanced bone formation and bone resorption. Since current PBKM do not account 
for the case of varying bone mass in adulthood, resulting either from diseases such as 
osteoporosis or from the natural changes in bone turnover with age [3,4], the bone Pb 
concentrations predicted by the models in such case may differ significantly from the 
real concentrations. Therefore, in order to avoid an imprecise description of Pb 
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metabolism such models should be revised to account for varying bone mass with age. 
Moreover, these results also show that Pb concentration in bones varies as a result of 
altered bone turnover, a question raised in previous work [23]. 
    
Another main finding of this study (experiment II) was that Pb exposure resulted in 
significantly increased serum CTX level and unaltered serum OC levels in female 
Wistar rats, showing that Pb exposure has the potential to disrupt the balance between 
bone formation and bone resorption which characterizes the turnover of healthy bone. It 
should be noted that the magnitude and significance of such effects seem to depend on 
the serum levels of OC and are more marked with decreasing levels of OC. The 
resemblance of these effects and their dependence on OC levels to those described in 
the literature for the OVX-induced decrease in bone mass [38] is noteworthy, despite 
the likely different mechanisms underlying the changes in bone metabolism resulting 
from OVX and Pb accumulation in bone. This emphasizes the role of OC as one of the 
factors involved in bone turnover, although its precise function is yet to be determined 
[29,30,38]. In addition, no significant contrasts for serum CTX were detected between 
exposed groups, suggesting that the interaction between exposure gradient and OC level 
did not induce a significant osteopenic effect, except when such gradient is maximum, 
as is the case between the lowest and highest exposure groups, and even so at the upper 
quartile of serum OC. Following these results, Pb exposure may lead to a reduction in 
bone mass which, along with disruption of bone architecture, defines osteoporosis [10]. 
Therefore, Pb may play a role in the etiology of this disease, although such role could 
not be established unequivocally because bone architecture was not assessed in this 
study. 
 
In view of current assumptions in PBKM, namely that Pb is incorporated in bone during 
bone formation and is removed from bone during bone resorption [3,4], it seems 
paradoxical that both osteopenia and increased half-life of Pb in bone, as suggested in 
this work and observed in previous studies [7,8], respectively, are apparently associated 
with higher exposures to Pb. This apparent paradox, however, can be explained by the 
methodological options of data analysis followed in this and previous studies. In fact, in 
previous work the level of exposure was considered alone as the main factor in the 
analytical model, with potential effect on the half-life of Pb in bone. Instead, in the 
current study the interaction between exposure and OC was included in the analytical 
model, and its effect on bone resorption was found to be significant and dominant in the 
model. Therefore, any direct comparison between the conclusions established on the 
impact of such interaction on bone turnover, and consequently on the half-life of Pb in 
bone, and the conclusions of previous work on the effect of exposure on the latter 
parameter can be misleading without further discussion. Moreover, in previous studies 
the half-life contrasts were estimated between cases of actual exposures to Pb while in 
this work the osteopenic effects were suggested following contrasts between the non-
exposed and exposed cases.  As a matter of fact, if only the estimated contrasts in bone 
resorption between actually exposed groups in this study were considered, then the 
current results would suggest that decreasing OC levels favor the increment of the half-
life of Pb in bone with increasing exposure. This is consistent with the conclusion that 
the half-life of Pb in bone is increased at higher exposure, established in previous work 
based on a sample 75% of which were Pb exposed subjects older than 40 years [8], and 
therefore with OC expectedly at the lowest levels according to published data [42]. As a 
final remark, such consistency is not undermined by the lack of statistical significance 
of the estimated contrasts in bone resorption between exposed groups in this work, 
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because even with a much larger sample not all half-life contrasts for compact and 
trabecular bone reach the traditional 5% level of significance [8].                   
 
In conclusion, this paper provides physiological evidence that Pb distributes differently 
in central compartments in Pb metabolism, such as cortical and trabecular bone, in 
healthy animals and animals with altered balance in bone turnover, and that exposure to 
Pb does have an impact on bone resorption resulting in OC-dependent osteopenia. 
These findings show that Pb may play a role in the etiology of osteoporosis and that its 
concentration in bones varies as a result of altered bone turnover characteristic of this 
disease. In addition, data collected in this study are consistent with previous 
observations of increased half-life of Pb in bone at higher exposures. This physiological 
evidence is relevant for the necessary revision of current PBKM for Pb, including 
possibly the new physiological skeletal model (PSM) recently developed [43] and 
which, to the best of the authors’ knowledge, has not been fit to epidemiological data on 
bone lead yet. This PSM is presented as an improvement on existing skeletal models, 
since it relies on structural concepts and kinetic parameters selected on the basis of 
physiological and anatomical criteria rather than on compartment structures which 
render good fits to biokinetic data. However, in a strict sense, it embodies a revision of 
existing models that preserves some of the main assumptions of older models and which 
were challenged by the physiological evidence provided by this study.   
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